Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis

• Register: ClinicalTrials.gov
• Last refreshed on: 19 October 2017
• Main ID: NCT01983787
• Date of registration: 11/07/2013
• Prospective Registration: No
• Primary sponsor: University of Aarhus
• Public title: Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis
• Scientific title: Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis
• Date of first enrolment: July 2013
• Target sample size: 10
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT01983787
• Study type: Observational

Countries of recruitment

Denmark

Contacts

• Name: Eskild Petersen, Professor
• Affiliation: Department of Infectious Diseases, Aarhus University Hospital, Denmark

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with Cystic Fibrosis, suffering from acute pulmonary exacerbations, treated
with continuous infusion of Piperacillin/Tazobactam for a period of two weeks.

Exclusion Criteria:

- Age under 18



Age minimum: 18 Years
Age maximum: 50 Years
Gender: All

Health Condition(s) or Problem(s) studied

Cystic Fibrosis

Primary Outcome(s)

Blood-plasma Concentration of Piperacillin [Time Frame: Piperacillin plasma-concentration was determined 3-5 times for each patient, during the 2 weeks of piperacillin treatment]

Secondary Outcome(s)

The Time Above the Minimum Inhibitory Concentration (T>MIC) [Time Frame: Patients will be followed for the duration of treatment, which is approximately 2 weeks.]

MIC of Pathogen Detected in Sputum Sample, Prior to Initiation of Treatment. [Time Frame: Sputum sample was collected 3 to 7 days before treatment initiation.]

Secondary ID(s)

CF-275-13

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 01/10/2015
• URL: https://clinicaltrials.gov/ct2/show/results/NCT01983787